Evidence map›Paper›PMID 40300786›Full record

Trial reportEuropean journal of heart failure2025

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR-HF2-DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials.

Stefan D Anker, Tim Friede, Javed Butler, Khawaja M Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak and 35 more

Registry-linked trialAbstract readClinical Trial, Phase IVComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03036462 (Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With IRon Deficiency and Chronic Heart Failure), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03036462 phase4completednot on this map

Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With IRon Deficiency and Chronic Heart Failure

TypeinterventionalSponsorUniversitätsklinikum Hamburg-EppendorfRan2017 to 2024Enrolled1,105ConditionsSystolic Heart Failure, Iron DeficiencyArmsIron, Saline
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Stefan D AnkerDeutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany.
Tim FriedeDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Javed ButlerDepartment of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Khawaja M TalhaDepartment of Cardiovascular Disease, Loyola University Medical Center, Maywood, Illinois, USA.
Marius PlaczekDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Monika DiekDeutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany.
Anna NoskoDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Adriane StasGerman Centre for Cardiovascular Research (DZHK), Partner Site Lower Saxony, Gottingen, Germany.
Stefan KlugeDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dominik JarczakDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Geraldine DeheerDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Meike RybczynskiDepartment of Cardiology, University Medical Center Hamburg-Eppendorf, University Heart & Vascular Center Hamburg, Hamburg, Germany.
Antoni Bayes-GenisHeart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV, Barcelona, Spain.
Frank EdelmannDepartment of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany.
Gerasimos FilippatosDepartment of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Gerd HasenfußGerman Centre for Cardiovascular Research (DZHK), Partner Site Lower Saxony, Gottingen, Germany.
Wilhelm HaverkampDeutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany.
Mitja LainscakDivision of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.
Ulf LandmesserGerman Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Iain C MacdougallDepartment of Renal Medicine, King's College Hospital, London, UK.
Bela MerkelyHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Burkert M PieskeDivision of Cardiology, Department of Internal Medicine, University Medicine Rostock, Rostock, Germany.
Fausto J PintoCentro Academico de Medicina de Lisboa, CCUL@RISE, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Tienush RassafWest German Heart- and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Maurizio VolterraniIRCCS San Raffaele Roma, Rome, Italy.
Stephan von HaehlingGerman Centre for Cardiovascular Research (DZHK), Partner Site Lower Saxony, Gottingen, Germany.
Markus S AnkerGerman Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Wolfram DoehnerDeutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charité Mitte, Berlin, Germany.
Hüseyin InceDivision of Cardiology, Department of Internal Medicine, University Medicine Rostock, Rostock, Germany.
Friedrich KoehlerGerman Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Gianluigi SavareseDepartment of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Berlin, Germany.
Ursula Rauch-KröhnertGerman Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Tommaso GoriDepartment of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany.
Teresa TrenkwalderTechnical University of Munich, School of Medicine and Health, Department of Cardiovascular Diseases, German Heart Centre Munich, TUM University Hospital, Munich, Germany.
Ibrahim AkinDepartment of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
Christina PaitazoglouDepartment of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Medical Clinic II, University Hospital Schleswig-Holstein, Lübeck, Germany.
Iwona Kobielusz-GembalaOświęcimskie Centrum Badań Klinicznych, Oswiecim, Poland.
Witold ZmudaOświęcimskie Centrum Badań Klinicznych, Oswiecim, Poland.
Luca KuthiHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Norbert FreyDepartment of Cardiology, Angiology and Pneumolgy, Clinical Trial Unit, University Hospital Heidelberg, Heidelberg, Germany.
Manuela LickaDepartment of Cardiology, Angiology and Pneumolgy, Clinical Trial Unit, University Hospital Heidelberg, Heidelberg, Germany.
Stefan KääbLMU Munich, Department of Medicine I, LMU University Hospital, Munich, Germany.
Karl-Ludwig LaugwitzGerman Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany.
Piotr PonikowskiInstitute of Heart Disease, Medical University and University Hospitals, Wroclaw, Poland.
Mahir KarakasDepartment of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPrior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency (ID). METHODS AND

resultsFAIR-HF2 is a double-blind, randomized, controlled trial evaluating the efficacy of IV ferric carboxymaltose in patients with HFrEF and ID. We report the baseline characteristics of enrolled patients and compare them with other major trials of IV iron in HFrEF (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, and HEART-FID). A total of 1105 patients were randomized between March 2017 and November 2023. Most patients were men (67%) and median age was 72 (interquartile range [IQR] 63-79) years. More than one-third had a heart failure hospitalization within the preceding 12 months (36%), and 53% were hospitalized at randomization. Common comorbidities included hypertension (79%), coronary artery disease (74%), dyslipidaemia (67%), and diabetes (46%). The median left ventricular ejection fraction was 58% (IQR 42-77) and mean estimated glomerular filtration rate was 58 (IQR 42-77) ml/min/1.73 m

conclusionThe FAIR-HF2 trial represents a contemporary cohort of patients with baseline characteristics mostly similar to prior trial populations. Use of SGLT2 inhibitors and ARNI in FAIR-HF2 was higher than in prior trials. CLINICAL

trial registrationClinicalTrials.gov ID NCT03036462.

Indexed as

Anemia, Iron-DeficiencyFerric CompoundsHeart FailureMaltoseAgedChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedMorbidityStroke VolumeTreatment Outcomeferric carboxymaltoseFerric CompoundsMaltoseClinical trialHeart failureHospitalizationIron deficiencyTransferrin saturation

Identifiers

PMID40300786
PMCPMC12482851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.